Initial Evaluation
Cobenfy will be approved when ALL of the following are met:
- The patient has an FDA labeled indication for the requested medication AND
- ONE of the following:
- There is evidence of a claim that the patient is currently being treated with the requested medication within the past 180 days OR
- The prescriber states the patient is currently being treated with the requested medication OR
- ALL of the following:
- The prescriber has assessed the patient’s liver enzymes and bilirubin prior to starting therapy with the requested medication AND
- The prescriber has assessed the patient’s heart rate prior to starting therapy with the requested medication AND
- ONE of the following:
- The patient has tried and had an inadequate response to TWO antipsychotic medications (e.g., aripiprazole, olanzapine, quetiapine, risperidone) for the requested indication OR
- The patient has an intolerance or hypersensitivity to TWO antipsychotic medications (e.g., aripiprazole, olanzapine, quetiapine, risperidone) OR
- The patient has an FDA labeled contraindication to TWO antipsychotic medications (e.g., aripiprazole, olanzapine, quetiapine, risperidone) AND
- The patient does NOT have any FDA labeled contraindications to the requested medication AND
- ONE of the following:
- The requested quantity (dose) does NOT exceed the program quantity limit OR
- ALL of the following:
- The requested quantity (dose) is greater than the program quantity limit AND
- The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit AND
- The prescriber has provided information in support of therapy with a higher dose for the requested indication
Length of Approval: 12 months
Renewal Evaluation
Cobenfy will be approved when ALL of the following are met:
- The patient has been previously approved for the requested medication through the plan’s Prior Authorization criteria AND
- The patient has an FDA labeled indication for the requested medication AND
- ONE of the following:
- There is evidence of a claim that the patient is currently being treated with the requested medication within the past 180 days OR
- The prescriber states the patient is currently being treated with the requested medication OR
- ALL of the following:
- The prescriber has assessed the patient’s liver enzymes and bilirubin as clinically indicated during treatment with the requested medication AND
- The prescriber has assessed the patient’s heart rate as clinically indicated during treatment with the requested medication AND
- The patient does NOT have any FDA labeled contraindications to the requested medication AND
- The patient has had clinical benefit with the requested medication AND
- ONE of the following:
- The requested quantity (dose) does NOT exceed the program quantity limit OR
- ALL of the following:
- The requested quantity (dose) is greater than the program quantity limit AND
- The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit AND
- The prescriber has provided information in support of therapy with a higher dose for the requested indication
Length of Approval: 12 months
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2026 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.